The Inflation Reduction Act and its price controls continue to damage the pharmaceutical industry as they limit innovation and patient access. The House Energy and Commerce Committee recently announced an oversight hearing will be held this coming Wednesday titled, “At What Cost: Oversight of How the IRA's Price Setting Scheme Means Fewer Cures for Patients.”
Read MorePharmacy Benefit Managers have been spreading misleading information, claiming that efforts to prevent their dishonest practices and enhance accountability equate to excessive government involvement in healthcare.
Read MoreAs TAPP has stated in the past, the Inflation Reduction Act and its price controls are damaging the pharmaceutical industry and preventing drug research. Now that this horrible piece of legislation is a year old, let's recap the many negative aspects of it.
Read MoreOn September 1, the Centers for Medicare and Medicaid Services will announce the first 10 Medicare Part D drugs chosen for the Medicare Drug Price Negotiation Program. This is the first of many steps in the wrong direction, all created by the Inflation Reduction Act that was signed into law a year ago.
Read MoreIn an impressive new ad, “Protecting America’s Future,” the American Edge Project advocates for online freedom in the United States and condemns foreign countries that abuse their power using the internet.
Read MoreExpanding on the Inflation Reduction Act of last year, the SMART Prices Act would aim to cap the prices of medicine. This may sound helpful, however, any short-term benefits would be overshadowed quickly by long-term damage.
Read MoreThe deceptively named legislation Lowering Drug Costs for American Families Act was recently introduced by House Democratic Health Committee leaders. The legislation was introduced by Frank Pallone, Jr. (D-NJ), Richard Neal (D-MA), and Robert “Bobby” Scott (D-VA), and it is meant to be an addition to the Inflation Reduction Act (IRA).
Read MoreTAPP submitted comments to the Centers for Medicare & Medicaid Services to oppose a proposed rule change regarding prescription drugs. Particularly, the rule change that would result in an annual survey, conducted by the federal government, on American life science companies.
Read MoreTAPP recently signed onto a letter addressed to leadership in the U.S. Senate Committee on Agriculture, Nutrition and Forestry and the U.S. House Committee on Agriculture to urge them to reform the U.S. sugar program.
Read MoreThe House Judiciary Committee held a hearing today on the Oversight of the Federal Trade Commission (FTC). The hearing focused on FTC chair Lina Khan and FTC’s market overreach and centralization of power.
Read MoreTAPP recently submitted comments to the Senate HELP Committee in response to Senator Bernie Sanders’s request for public input on the proposed “reasonable pricing” scheme.
Read MoreResearch firm Vital Transformation modeled the impacts of government mandated drug pricing schemes currently proposed as the Smart Prices Act (SPA). The SPA would impose government price setting for certain Medicare drugs at only five years after initial FDA approval.
Read MoreTAPP submitted comments to the USPTO in response to their request for public input on proposed rule changes regarding discretionary institution practices, petition word-count limits, and settlement practices for America Invents Act trial proceedings before the Patent Trial and Appeal Board (PTAB).
Read MoreA recent report from Vital Transformation estimated and modeled the Inflation Reduction Act’s (IRA) impact on innovation and the ability of the life science industry to create new medicines
Read MoreA recent American Edge Project survey polled U.S. and European voters on domestic and foreign technology issues.
Read MoreThe American Edge Project (AEP), a coalition of two dozen domestic organizations, which includes the Trade Alliance to Promote Prosperity, has released a policy report underscoring the importance of maintaining a free and open internet amid the mounting threat posed by digital autocracies such as China and Russia.
Read MorePresident Biden reignited the Cancer Moonshot program in February 2022, announcing a national goal of cutting the death rate from cancer by at least 50 percent over the next 25 years. This is a noble and important goal that Americans can get behind. Medical innovators will be essential to the fight against cancer over the next 25 years.
Read MoreTariffs should be respected or repealed—not flouted. TAPP launched the “Tariff Integrity” initiative to urge the U.S. Trade Representative to crack down on foreign businesses evading tariffs on aftermarket automobile parts and to fight for tariff integrity.
Read MoreThe Trade Alliance to Promote Prosperity sent a letter to members of the U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee, urging the enactment of Pharmacy Benefit Manager reforms.
Read MoreTAPP recently submitted comments to the U.S. International Trade Commission to express concerns with a possible expansion of the TRIPS waiver beyond COVID-19 vaccines.
Read More